SF3B1 and myelodysplastic syndrome: Out of 38 MDS patients, SF3B1 was mutated in 13% of the cases (n = 5), and these SF3B1 mutations were significantly associated with response to XPO1 inhibition (selinexor and eltanexor) (Fig. 1B).